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Abstract
Background: Studies focused on the correlation of mutations in the genome of Hepatitis B Virus (HBV) like Pre-S mutation,
Basal Core promoter (BCP), Enhancer II (EnhII), especially Precore mutation, with the risk of hepatocellular carcinoma (HCC)
have triggered stiff controversies. With an increasing number of studies in this field recently, we conducted this meta-
analysis to appraise the correlations.
Methods: We searched the commonly used databases both in English and Chinese till February 1
st, 2012. Meta-analysis was
performed in fixed/random-effects models using STATA 10.0. Publication bias was examined through Egger’s test and
Begg’s funnel plot.
Results: In total, 85 case-control studies were included involving 16745 HBV-infected patients, of whom 5781 had HCC.
Statistically significant correlations were observed in Precore mutation G1896A (OR=1.46, 95% confidence interval
[CI]=1.15–1.85, POR=0.002), G1899A (OR=3.13, 95%CI=2.38–4.13, POR,0.001) and Pre-S mutation especially Pre-S1
deletion (OR=2.94, 95%CI=2.22 to 3.89) and Pre-S2 deletion (OR=3.02, 95%CI=2.03 to 4.50). Similar correlation existed
between BCP double mutation A1762T/G1764A, T1753V, C1653T and HCC. In subgroup analysis, the Asians, genotype C or
HBeAg positive patients with certain above mutations may be more susceptible to HCC. Besides, the mutations like G1896A
and BCP double mutation may be associated with the progression of the liver diseases.
Conclusions: Precore mutation G1896A, G1899A, deletions in Pre-S region as well as the other commonly seen mutations
correlated with the increased risk of HCC, especially in Asians and may predict the progression of the liver disease.
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Introduction
Hepatocellular carcinoma (HCC) is the primary histological
subtype of the liver cancer which ranks the fifth most prevalent
cancer worldwide and the second leading cause of the cancer
mortality [1]. The main factors attributing to HCC encompass the
chronic hepatitis B virus (HBV) and/or hepatitis C virus (HCV)
infection etc., while the main reason for HCC comes to the
chronic infection with HBV [2,3].
HBV contains an incomplete double-stranded DNA genome
consisting of four main regions: the PreS/S region (nucleotides or
nt 2854–155), the enhancer II(EnhII; nt 1636–1744) region, basal
core promoter (BCP, nucleotides 1751–1769) region and the
precore region. It has been demonstrated that mutations in the
HBV genome which is pertinent to HCC invariably occur at the
PreS region, EnhII, BCP and precore region. Those mutations
include G1613A, C1653T in the EnhII region; T1753V, the
double mutation A1762T/G1764A at the BCP region, G1896A
and G1899A in the precore region [4,5]. Several prospective
studies demonstrated that patients who had A1762T/G1764A
double mutation were more predisposed to HCC than those with
the wild type [4,6]. Similar associations with HCC can be found in
mutations in the precore region as well as that in the EnhII region
[7,8]. The PreS mutation generally presents in form of deletions
[9–11]. And it primarily comprises of PreS1 deletion and PreS2
deletion. The PreS1 and PreS2 regions are vital for the interaction
with the host immune responses [12]. Thus the mutations occur in
the PreS region would contribute to the inefficient immune
response and ultimately lead to hepatocarcinogenesis. Therefore,
ascertaining the relationship between the mutations in HBV
genome and the occurrence of HCC may prompt the advance-
ment in predicting the occurrence of HCC, screening the genetic
predisposition as well as developing the clinical treatment regimes.
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ation between these mutations and the onset of HCC [13–15]. To
illuminate the controversy, a related meta-analysis was performed
and demonstrated a positive relationship between the mutations
like BCP double mutation, Pre-S mutation, C1653T and T1753V
and the occurrence of HCC, while no significance was observed in
Precore mutation G1896A [16]. Till now, much more studies
(around 40 more case-control studies) focusing on the correlation
of HBV mutations with HCC have emerged and increasing studies
demonstrated a significant correlation between Precore G1896A
and the risk of HCC [4,17–19]. Besides, a new mutation pattern
G1899A in precore region appears to significantly correlate with
the incremental risk of HCC [4,17,20,21] as well. Moreover, for
Pre-S mutation, more studies focused on Pre-S1 deletion and Pre-
S2 deletion [9,22,23] respectively and it would be of great help in
discerning the contribution each mutation in Pre-S region made to
HCC risk through analyzing their effects respectively. Thus it’s
imperative to update this meta-analysis to give us a more
comprehensive understanding on those mutations with HCC risk.
Therefore we reappraised the relationship between the ubiquitous
mutations and the risk of suffering from HCC in this study, with
great attention paying to Precore G1896A and the HCC risk.
Materials and Methods
Search strategy for the original article
A comprehensive search was conducted till February 1
st 2012
using the following databases: PUBMED, Embase, Chinese
Biomedical Literature Database (CBM) and China National
Knowledge Infrastructure (CNKI). Medical Subject Heading
(MeSH) terms were of the priority in setting the strategy. The
key words were ‘‘hepatitis b virus’’ ‘‘mutation’’ and ‘‘hepatocel-
lular carcinoma’’. In addition, we scrutinized the reference
citations in the retrieved articles so as not to miss any additional
eligible studies.
Criteria for article screening
Studies were included if they met the following criteria: 1) the
article assessed the association between HBV mutations and HCC;
2) study design was a case-control study; 3) the diagnosis of each
stage of liver disease conformed to the American Association for
the Study of Liver Disease [12,24]; 4) odds ratio with the 95%
confidence interval was reported or could be figured out through
the available data. The unpublished reports like the conference
abstracts were not included. We excluded articles that had no
control group, case and control number less than 10 respectively,
as well as patients who have co-infection with HCV and/or HIV
or patients with liver disease caused by other non-infection
reasons. As for the studies conducted by the same author, if the
two inclusion time overlapped for more than 30% of the study
time or all the patients were from the same region, we only
adopted the most recent article or the one with the larger case
number. While those studies written by the same author focused
on distinct mutations were still included.
Data collection
The data was collected by two members (Yun Liao and Xin Hu)
independently, using the standardized form. When any discrep-
ancy occurred, we consulted with the other investigators until the
consensus was reached. The following information was extracted:
first author’s name, publication time, country, ethnicity, study
design, sequencing method, number of cases (patients who have
developed HCC) and controls (patients without HCC), mean age,
male proportion, genotype distribution and mutation sites. Still,
we extracted data based on subgroups like ethnicity, genotypes
and HBeAg statuses etc.
Statistical analysis
The impact the mutations have on HCC were estimated by
summary odds ratios (OR) and their corresponding 95%CI. The
overall effect was appraised through the Z test which could be
deemed significant if the P value was less than 0.05. The
heterogeneity for the included articles was evaluated using
Cochran’s Q test, I
2 statistics (the heterogeneity could be accepted
if P.0.1 and I
2#50%) and Galbraith plot for heterogeneity. If the
value of I
2 statistics was less than 50% or the P value is more than
0.1, the fixed-effects model can be tapped, otherwise, random-
effects model be used. Galbraith plot was used to determine the
main sources of the heterogeneity. Begg’s funnel plot and Egger’s
test were performed to examine the publication bias. All the
statistical analyses were performed using STATA (version 10.0).
All tests were two sided.
Results
Study selection
The flow diagram (See Figure 1) describing the screening
process was modified according to the PRISMA Statement [25].
After skimming the titles and abstracts, 104 articles were included
for full text view. Among them, seven articles were not case-
control studies [26–32], one with co-infection patients [33], one
with occult HBV infection [34], three with case and control
number less than 10, respectively [35–37], one article was
inaccessible [38] and six other studies with repetitive results
(reference not shown). Finally, 85 case-control studies were
included, among which, 43 case-control studies focused on
G1896A, 56 studies on A1762T/G1764A, 24 studies on Pre-S
mutation, 27 studies on T1753V and 23 studies on C1653T. The
characteristics of the qualified articles were summarized in Table
S1.
Precore mutations and HCC risk
For the controversial Precore mutation G1896A, 43 studies
were included in the meta-analysis. Heterogeneity existed among
all the studies (I
2=77.6%, P,0.001), thus the random-effects
model was used. Significant correlation was found between
G1896A and the occurrence of HCC (summary OR=1.46;
95%CI=1.15–1.84) (See Figure 2A). When performing Galbraith
Plot for Heterogeneity, we observed ten outliers (See Figure 3A) as
the main source of heterogeneity. Then we omitted these ten
studies and reappraised the correlation. Still significant correlation
was found with no statistically heterogeneity existed (ORad-
justed=1.33, 95%CI=1.16–1.53, I
2=14.3%, Pheterogeneity=0.237)
(See Table 1; Figure 2B). In the subgroup analysis by ethnicity, the
results indicated that G1896A correlated with an increased risk
among the Asians (OR=1.47, 95% CI=1.16–1.92,) and even
after adjustment for heterogeneity (OR=1.33, 95% CI=1.14–
1.54), while no such correlation was found in Caucasians and
Africans (See Table 1). For subgroup analysis by genotype,
especially in genotype C, great heterogeneity existed (I
2=85.4%,
P=0.107). According to Galbraith plot, studies conducted by Lyu
H [39], Yin J [4], and Tanaka [40] were three outliers (data not
shown). After omitting these three, significant correlation was
observed (OR=1.34, POR=0.041, I
2=39.2%). While for HBeAg
status subgroup, we didn’t observe any significant association, but
the trend toward significant association became increasingly
obvious (See Table 1).
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studies including 693 cases and 953 controls were included. No
statistically significant heterogeneity existed (I
2=33.0%, Phetero-
geneity=0.135) and the fixed-effects model was used. Results
showed that G1899A correlated with an increased risk of HCC
(OR=3.13, 95%CI=2.38–4.13) (See Figure 4). In subgroup
analysis by ethnicity, a significant association was found to exist
between G1899A and HCC in Asians (OR=3.22, 95%CI=2.42–
4.28). While only one study [41] focused on the Africans and no
correlation was found.
Pre-S deletions and HCC risk
For Pre-S mutation, we primarily focused on Pre-S1 deletion
and Pre-S2 deletion. 11 articles including 807 HCC cases and
1820 controls were included for Pre-S1 deletion and no significant
heterogeneity was observed (I
2=3.9%, P=0.411). Thus fixed-
effects model was used to appraise the association between Pre-S1
Figure 1. Flow chart for article screening in the meta-analysis. After a comprehensive screening, a total of 85 case-control studies were
identified.
doi:10.1371/journal.pone.0038394.g001
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(OR=2.94, 95%CI=2.22–3.89) (See Figure 5A). For Pre-S2
deletion, 13 articles including 690 cases and 1140 controls were
included. Heterogeneity seemed to exist (I
2=43.3%) and random-
effects model was used. The results indicated a significant
correlation existed (OR=3.02, 95% CI=2.03–4.50) (See
Figure 5B). Galbraith plot was used to determine the heterogeneity
source and found Chen CH [21] was the sole outlier (See
Figure 3B). After omitting that, significant correlation with no
Figure 2. Forest plot for the correlation between Precore mutation G1896A and HCC risk. (A) Pooled odds ratio for correlation of Precore
G1896A with HCC (before adjustment for heterogeneity). (B) Pooled odds ratio for association between G1896A and HCC risk after adjustment for
heterogeneity. (For the forest plot, the black diamond represented the OR estimate for each study and the size of the grey area reflected the weight
in the pooled analysis; the horizontal line indicates the 95% confidence interval (CI); the white diamond represented the pooled odds ratio).
doi:10.1371/journal.pone.0038394.g002
Figure 3. Galbraith plots for heterogeneity test of G1896A and Pre-S2 deletion. (A) Galbraith plot of the association between precore
G1896A and HCC risk (The studies outside the range between 22 and 2 were seen as the outliers and the major source of heterogeneity); (B)
Galbraith plot of the correlation between Pre-S2 deletion and HCC risk.
doi:10.1371/journal.pone.0038394.g003
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4.73, I
2=16.8%).
The other common mutations and HCC risk
In our study, we appraised the correlation between the other
common mutations like BCP double mutation, C1653T etc. For
these mutations, statistically significant heterogeneity was observed
for BCP double mutation (I
2=76.1%, p,0.001), T1753V
(I
2=71.4%, p,0.001) and C1653T (I
2=60.8%, p,0.001). Thus,
for these mutations, random-effects model was used. Results
showed that BCP double mutation A1762T/G1764A strongly
correlated with the occurrence of HCC (OR=3.98,
95%CI=3.19–4.95) (See Figure S1); T1753V associated with a
2.23-fold risk (95% CI=1.69–2.93) (See Figure S2), and C1653T
with a 2.55-fold increased risk of HCC (95%CI=1.95–3.35) (See
Table S2, Figure S3).
In subgroup analysis by ethnicity, all the mutations correlated
with the risk of HCC in Asians (For A1762T/G1764A,
OR=4.20, p,0.001; T1753V, OR=2.19, p,0.001; C1653T,
OR=2.61, p,0.001). In subgroup analysis by genotype,
A1762T/G1764A in HBV genotype B and C, T1753V in HBV
genotype C and D, C1653T in genotype C patients significantly
correlated with the increased risk of HCC. While in HBeAg
subgroup, BCP A1762T/G1764A was associated with the
increased risk of HCC irrespective of the HBeAg status. But in
HBeAg positive group, BCP double mutation correlated with a
higher risk than in negative group. While for C1653T, a higher
risk susceptible to HCC could be seen in the negative group (See
Table S2).
Besides, during the process of extracting data, we found an
escalating trend of the mutant rate accompanying the progression
of the disease and almost no difference could be observed between
liver cirrhosis group and HCC group [4]. Therefore we
categorized the four stages of disease state from asymptomatic
carrier to HCC into two groups: HCC and liver cirrhosis as the
progressive disease group, asymptomatic and chronic carrier as the
Table 1. Summary of the odds ratio and its 95% Confidence Interval in the meta-analysis.
Mutations/Subgroup analysis
No. of









Total 43 1.458 (1.153, 1.845) 0.002 77.6% 0.000 R 20.14 0.891
Total (adjustment
=) 33 1.328 (1.155, 1.528) 0.000 14.3% 0.237 F 1.01 0.319
Subgroup analysis by ethnicity
Asians 38 1.492 (1.158, 1.923) 0.002 79.5% 0.000 R
Asians(adjustment) 28 1.325 (1.140, 1.540) 0.000 12.5% 0.278 F
Caucasian 1 0.162 (0.018, 1.479) 0.107 / / -
African 2 1.291(0.751, 2.219) 0.355 0.0% 0.401 F
Mixed 2 1.774 (0.988, 3.187) 0.055 27.6% 0.240 F
Subgroup analysis by genotype
Genotype B 4 2.665 (0.874, 8.127) 0.085 79.9% 0.002 R
Genotype C 11 1.540(0.911, 2.603) 0.107 85.4% 0.000 R
Genotype C(adjustment) 8 1.344 (1.013,1.784) 0.041 39.2% 0.118 F
Genotype D 2 0.750 (0.038,14.972) 0.851 / / F
Subgroup analysis by HBeAg
HBeAg negative 4 1.339 (0.925, 1.940) 0.122 26.5% 0.253 F
HBeAg positive 4 1.382 (0.804, 2.376) 0.242 43.9% 0.148 R
Precore G1899A
Total 11 3.134 (2.376, 4.134) 0.000 33.0% 0.135 F 0.63 0.543
Subgroup analysis by ethnicity
Asian 10 3.221 (2.423, 4.282) 0.000 37.3% 0.110 F
African 1 1.895 (0.565, 6356) 0.301 / / F
Pre-S mutaton
Pre-S1 deletion
Total 11 2.939 (2.222, 3.886) 0.000 3.9% 0.411 F 21.66 0.132
Pre-S2 deletion
Total 13 3.017 (2.025, 4.496) 0.000 43.3% 0.048 R 2.43 0.033
Total(adjustment) 12 3.510 (2.605, 4.729) 0.000 16.8% 0.279 F 1.74 0.113
*POR value for the odds ratio.
#PH the P value of the Heterogeneity test.
1T for Egger’s test, Pegger, the P value for Egger’s test.
R for the Random-effects model, F for the Fixed-effects model.
=Adjustment for Heterogeneity by omitting the most obvious outliers.
doi:10.1371/journal.pone.0038394.t001
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mutations with the progression of disease were found. BCP double
mutation had the strongest association with the progressive disease
group (summary OR=5.46, 95%CI: 3.88–7.67). The odds ratio
for T1753V was 2.77 (95%CI=1.92–4.01), for C1653T was 2.59
(95%CI=1.53–4.37). Moreover, we still observed significant
correlation between G1896A and the progressive disease group
with an OR=1.85 (95%CI=1.27–2.70) (See Table S2).
Publication bias
Publication bias was only found in Pre-S2 deletion through
egger’s test (P=0.033). From Galbraith plot, we saw Chen CH
[21] was the outlier. After omitting this study, heterogeneity
greatly decreased from 43.3% to 16.8%. Then we reappraised the
publication bias of Pre-S2 deletion and found no bias existed
through egger’s test (p=0.113). The Begg’s funnel plot seemed
symmetrical as well (See Figure 6). No publication bias was found
among the other mutations (See Table 1).
Sensitivity analysis
For all the mutations, sensitivity analysis was performed by
sequential omission of every study respectively. For every
mutation, the odds ratio was not significantly influenced by
omitting any single study (See Table S3).
Discussion
Our study showed that Precore mutation G1896A and
G1899A, Pre-S1 deletion, Pre-S2 deletion and other common
mutations mentioned above were all independently associated with
an increased risk of HCC as well as the progression of liver
diseases.
Mutation G1896A locates at nt.1896 in the precore region
leading to a G-to-A shift, which could induce a stop codon and
subsequently suppress the expression of HBeAg [42]. Though it
would cease the production of HBeAg, the HBV DNA would still
be synthesized in patients and eventually contribute to the
progression of liver disease to a more advanced stage [10]. It
was once reported that G1896A correlated with severe forms of
liver diseases [43]. Yin and his colleagues who did the former
meta-analysis [16] also reported a significant association between
G1896A and HCC with an OR=5.10 in genotype B and 3.60 in
genotype C patients in their recent research [4]. In our study,
when pooling data from 43 studies including 3097 cases and 5530
controls, statistically significant association was determined
between G1896A (OR=1.46; p=0.002) and the increased risk
of HCC, which was totally different from Yin’s [16] conclusion
whose summary OR was 1.15 (95%CI=0.83–1.60), pooling data
from 24 studies. The discrepancy between our study and the
previous one would attribute to the statistically power of detecting
Figure 4. Forest plot for the correlation between Precore mutation G1899A and HCC risk.
doi:10.1371/journal.pone.0038394.g004
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results after omitting the outliers and the sensitivity analysis again
consolidated what we have gleaned. In subgroup analysis, we
found correlation existed among Asians, but not in Caucasians or
Africans. That might be due to insufficient studies focusing on the
latter two populations. For genotype and HBeAg status subgroup,
Figure 5. Forest plot for the correlation between Pre-S deletions and HCC risk. (A) Pooled odds ratio for correlation of Pre-S1 deletion and
HCC risk using fixed-effects model; (B) Pooled odds ratio for association of Pre-S2 deletion and HCC risk using random-effects model.
doi:10.1371/journal.pone.0038394.g005
Figure 6. Funnel plot of association between Pre-S2 deletion and HCC risk (After adjustment for heterogeneity).
doi:10.1371/journal.pone.0038394.g006
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studies, but the trend toward increasing the risk of HCC became
obvious. Thus large-number, well-designed case-control studies
are entailed in elucidating the relationship between G1896A and
HCC risk.
Besides, G1899A also locates at Precore region of HBV genome
and associated with a 3.14-fold increased risk of HCC compared
with HBV patients without G1899A. For the mechanisms that
underlie the interaction between G1899A and the onset of HCC
still remain elusive. They may act as G1896A does but still merit
further exploration. So far, this study is the first to report that
significant correlation exists between G1899A and the increased
risk of HCC based on a powerful meta-analysis, which might be a
potential biomarker for foreseeing the occurrence of HCC.
Pre-S1 deletion and Pre-S2 deletion are the two most commonly
seen mutations in Pre-S region. From our study, both types of
mutations significantly correlated with the increased risk of HCC
(For Pre-S1: OR=2.94, p,0.001; Pre-S2: OR=3.02, p,0.001).
The deletion in Pre-S region would cause inefficient immune
response and the pathogenesis of hepatocytes [43] and thus lead to
the development of HCC. Given the significant association with
HCC, the two mutations might be independently used as the
biomarker for predicting the occurrence of HCC.
For the other common mutations, BCP double mutation
A1762T/G1764A is generally accepted that it independently
correlates with the risk of HCC and the progression of liver
diseases [44], which is consistent with our results. For C1653T and
T1753V, significant correlations with HCC are still observed in
the two mutations. Though from Galbraith plot, we observed at
least five outliers for each mutation (See Figure S4). This time we
did not adjust the heterogeneity and reappraise the correlation
since they have been generally accepted as the risk factors.
Additionally, the sensitivity analysis confirmed that these muta-
tions did strongly correlate with the risk of HCC. Thus our results
are trustful.
From subgroup analysis by ethnicity, we could see that all the
mutations mentioned in our study correlated with HCC among
Asians, which might indicate that Asians would be more
vulnerable to HCC. While for the relationship between genotypes
and HCC, though the role of genotype in hepatocarcinogenesis
remains elusive, several studies conducted in East Asia have
proved that genotype C was more likely to cause severe liver
disease like HCC than genotype B [45–47]. From our subgroup
analysis, we may conclude that HBV genotype C patients with
certain mutations like BCP double mutation, C1653T and
T1753V would be exposed to a much higher risk of HCC. While
genotype B has a moderate effect with such mutation on HCC
compared to genotype C which is consistent with those previous
studies. When stratified by HBeAg statuses, BCP double mutation
and positive HBeAg status may have synergistic effect on the
occurrence of HCC. For the other mutations, more studies are
necessitated to explore the impact these mutations have on
patients with different HBeAg statuses.
For the four stages of liver diseases, when we divided them into
two groups: HCC and LC; chronic hepatitis and asymptomatic
carrier, we found that the higher the incidence of HBV mutations,
the more severe the liver disease. We found a 5.46-fold increased
risk of HCC and LC in BCP double mutation, 2.77-fold in
T1753V and 2.59-fold in C1653T. Precore G1896A was still
associated with the progressive diseases contributing to a 1.85-fold
increased risk suffering from a more severe disease status. Besides,
Yin and his colleagues [4] also reported the correlation between
these mutations and the liver disease progression, which coincided
with our conclusion. Based on these, we may infer that these
mutations would have accumulative effects in the development of
the liver diseases and therefore a higher frequency of occurrence
could be observed in HCC and LC. Meanwhile, their roles in
promoting the development of a severer liver disease status could
in part explain their associations with HCC onset. Thus these
mutations may additionally contribute to the progression of liver
disease, apart from their influences on the occurrence of HCC.
However, our study has several limitations. Firstly, a large
number of studies were included in this study, and inevitably there
existed heterogeneity which could not be easily eliminated. Thus
we adopted random-effects model. When doing the sensitivity
analysis, the odds ratios were not significantly affected. Therefore
it should not influence the accuracy of our results. Secondly, when
adjusting for heterogeneity, we excluded those outliers seen from
Galbraith plot and during the excluding process, extra bias might
be introduced. Thirdly, when taking subgroup analysis, only a few
studies were available and the evidence seemed insufficient as well
as unconvincing. Fourthly, since few studies involved the
evaluation of the combination effects of these mutations on
HCC, we did not summarize the total effects for the combination
of these mutations. Lastly, only the data of those published articles
in English or Chinese can be extracted and a potential bias would
thus be introduced. Given these limitations, what we have found in
this study should be interpreted prudently.
Despite these limitations, our study indicates that Precore
mutation G1896A is significantly associated with the increased risk
of HCC and the progression of liver disease, especially among
Asians. Besides, G1899A, Pre-S1 deletion, Pre-S2 deletion as well
as other common mutations like BCP double mutation A1762T/
G1764A, T1753V and C1653T, all of them correlate with HCC
risk. For those results in subgroup analysis, they still need large-
scale, well-designed case-control studies to prove. Since the
development of the hepatocellular carcinoma can be attributed
to multiple factors, what we have observed is only the tip of the
iceberg. The future study could concentrate on the interaction of
epigenetic influence as well as the genetic variations. Certainly, the
environment and the host factors should be taken into consider-
ation.
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